140 reports of this reaction
2.5% of all CARVEDILOL PHOSPHATE reports
#6 most reported adverse reaction
HEADACHE is the #6 most commonly reported adverse reaction for CARVEDILOL PHOSPHATE, manufactured by Waylis Therapeutics LLC. There are 140 FDA adverse event reports linking CARVEDILOL PHOSPHATE to HEADACHE. This represents approximately 2.5% of all 5,587 adverse event reports for this drug.
Patients taking CARVEDILOL PHOSPHATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for CARVEDILOL PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for CARVEDILOL PHOSPHATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 140 FDA reports for CARVEDILOL PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.5% of all adverse event reports for CARVEDILOL PHOSPHATE, making it a notable side effect.
If you experience headache while taking CARVEDILOL PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.